Clinical Trial Update: Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of sublingual immunotherapy for allergic rhinitis caused by Artemisia annua has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Allergic Rhinitis | Phase 3 | Status: COMPLETED